Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 16 of 16 publications.

Kawai A, Fuller CC, Koram N, Agan A, Brown J, Burk J, Cai B, Daniels K, Fearrington J, Franklin JM, Hague C, Jamal-allial A, Johannes CB, Kempner M, Layton JB, Ma Q, Mai X, Mayer SE, Pawloski PA, Reynolds JS, Seals RM, Selvan M, Smith S, McMahill-Walraven CN, Gilsenan A, Platt R. Monitoring results from a postapproval safety study of Pfizer-BioNTech COVID-19 vaccine in the United States: vaccine utilization and incidence rates of myocarditis/pericarditis. Poster presented at the 39th ICPE Annual Conference; August 25, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):182. doi: 10.1002/pds.5687

Mayer SE, Fuller CC, Haynes K, Alam S, Brown JS, Daniels K, Hawrusik R, Horgan C, Jamal-allial A, Johannes CB, Kawai AT, Layton JB, Mai X, Marshall J, McMahill-Walraven CN, Reynolds JS, Seals R, Selvan M, Stemkowski S, Wang FT, Yost E, Gilsenan A, Platt R. Use of Janssen Ad26.COV2.S COVID-19 Vaccine (JCOVDEN) and mRNA COVID-19 vaccines in four large US national insurers. Poster presented at the 39th ICPE Annual Conference; August 25, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):186. doi: 10.1002/pds.5687

Sweeney C, Calingaert B, Holzmann R, Moeller C, Schomakers G, Sok A, Pisa F, Gilsenan A. Physician knowledge of safe use of cyproterone acetate monotherapies and meningioma. Poster presented at the 39th ICPE Annual Conference; August 26, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):300. doi: 10.1002/pds.5687

Gilsenan AW, Hammad TA, Juhaeri J, Mansfield C, Levitan BS. Weighting the benefits & risks: the science and methods of benefit-risk assessment in drug development. Presented at the 39th ICPE Annual Conference; August 23, 2023. Halifax, Canada. Previously presented at the 2022 ICPE Conference.

Johannes CB, Beachler DC, Layton JB, Danysh HE, Ziemiecki R, Arana A, Dinh J, Li L, Calingaert B, Pladevall-Vila M, Hunt PR, Chen H, Karlsson C, Johnsson K, Gilsenan A. Post-authorization safety study of hospitalization for acute kidney injury in patients with type 2 diabetes exposed to dapagliflozin in a real-world setting. Drug Saf. 2023 Feb 1;46(2):157-74. doi: 10.1007/s40264-022-01263-3

Danysh HE, Johannes CB, Beachler DC, Layton JB, Ziemiecki R, Arana A, Dinh J, Li L, Calingaert B, Pladevall-Vila M, Hunt PR, Chen H, Karlsson C, Johnsson K, Gilsenan A. Post-authorization safety studies of acute liver injury and severe complications of urinary tract infection in patients with type 2 diabetes exposed to dapagliflozin in a real-world setting. Drug Saf. 2023 Feb 1;46(2):175-93. doi: 10.1007/s40264-022-01262-4

Chirila C, Gilligan TM, Gilsenan A, Price M, Hollis K, Calingaert B, Zografos L, Andrews E. A comparison of factors influencing patient knowledge: results across selected REMS surveys. Poster presented at the 27th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 18, 2011. Chicago, IL.

Gilsenan A, Hollis K, Zografos L, Calingaert B, Andrews E. Examination of respondent bias and patient characteristics in multiple REMS assessment surveys. Poster presented at the 27th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 18, 2011. Chicago, IL.

Gilsenan A, Harris DH, Midkiff K, Wright J, Andrews E. Linking with multiple state cancer registries for safety surveillance study – Is it feasible? Poster presented at the 27th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 18, 2011. Chicago, IL.

Midkiff KD, Harris D, Gilsenan AW, Wu Y, Andrews EB. Drug safety studies using cancer registry data: confluence of elements impacting the interview response rate. Poster presented at the 27th International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 14, 2011. Chicago, IL. [abstract] Pharmacoepidemiol Drug Saf. 2011 Aug 1; 20(Suppl. 1):S231. doi: 10.1002/pds.2206

Midkiff KD, Gilsenan AW, Wu Y, Harris DH, Masica D, Andrews EB. Using cancer registry data to advance the science of drug safety: results from an ongoing postmarketing drug safety surveillance study of adult osteosarcoma. Presented at the North American Association of Central Cancer Registries Annual Conference; June 21, 2011. Lexington, KY.

Mintz ML, Yawn BP, Mannino DM, Donohue JF, Hanania NA, Grellet CA, Gilsenan AW, McLeod LD, Dalal AA, Raphiou IH, Prillaman BA, Crater GD, Cicale MJ, Mapel DW. Prevalence of airway obstruction assessed by lung function questionnaire. Mayo Clin Proc. 2011 May 1;86(5):375-81.

Levitan BS, Andrews EB, Gilsenan A, Ferguson J, Noel RA, Coplan PM, Mussen F. Application of the BRAT framework to case studies: observations and insights. Clin Pharmacol Ther. 2011 Feb 1;89(2):217-24. doi: 10.1038/clpt.2010.280

Andrews EB, Midkiff KD, Gilsenan AW, Harris DH. Collaboration with multiple state cancer registries for a data linkage drug safety surveillance study – yes you can!. Poster presented at the North American Association of Central Cancer Registries Annual Conference; 2011.

Gilsenan AW, Midkiff KD, Harris DH. Opportunities for improving the use of cancer registry data in drug safety studies: factors influencing interview response rate. Presented at the North American Association of Central Cancer Registries Annual Conference; 2011.

Midkiff KD, Gilsenan AW, Harris DH, Wu Y, Masica D, Andrews EB. Exposure to possible osteosarcoma risk factors in a US postmarketing osteosarcoma surveillance study. Poster presented at the Scandinavian Sarcoma Group Annual Meeting; 2011.